These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32728158)

  • 21. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
    McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
    J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epoxyeicosatrienoic intervention improves NAFLD in leptin receptor deficient mice by an increase in PGC1α-HO-1-PGC1α-mitochondrial signaling.
    Raffaele M; Bellner L; Singh SP; Favero G; Rezzani R; Rodella LF; Falck JR; Abraham NG; Vanella L
    Exp Cell Res; 2019 Jul; 380(2):180-187. PubMed ID: 31039348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease.
    Stacchiotti A; Favero G; Lavazza A; Golic I; Aleksic M; Korac A; Rodella LF; Rezzani R
    PLoS One; 2016; 11(1):e0148115. PubMed ID: 26824477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-Week Isocaloric Time-Restricted Feeding Decreases Liver Inflammation without Significant Weight Loss in Obese Mice with Non-Alcoholic Fatty Liver Disease.
    Wilson RB; Zhang R; Chen YJ; Peters KM; Sawyez CG; Sutherland BG; Patel K; Kennelly JP; Leonard KA; Jacobs RL; Wang R; Borradaile NM
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
    Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
    J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
    Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions.
    Liu J; Jiang S; Zhao Y; Sun Q; Zhang J; Shen D; Wu J; Shen N; Fu X; Sun X; Yu D; Chen J; He J; Shi T; Ding Y; Fang L; Xue B; Li C
    J Pathol; 2018 Nov; 246(3):277-288. PubMed ID: 29971772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
    Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
    J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
    Park HS; Hur HJ; Kim SH; Park SJ; Hong MJ; Sung MJ; Kwon DY; Kim MS
    Mol Nutr Food Res; 2016 Sep; 60(9):1944-55. PubMed ID: 27145114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis.
    Herrero-Cervera A; Vinué Á; Burks DJ; González-Navarro H
    Diabetologia; 2019 Nov; 62(11):2143-2157. PubMed ID: 31388695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease.
    Romero-Zerbo SY; García-Fernández M; Espinosa-Jiménez V; Pozo-Morales M; Escamilla-Sánchez A; Sánchez-Salido L; Lara E; Cobo-Vuilleumier N; Rafacho A; Olveira G; Rojo-Martínez G; Gauthier BR; González-Mariscal I; Bermúdez-Silva FJ
    Front Endocrinol (Lausanne); 2020; 11():103. PubMed ID: 32210914
    [No Abstract]   [Full Text] [Related]  

  • 38. A novel and selective melanin-concentrating hormone receptor 1 antagonist ameliorates obesity and hepatic steatosis in diet-induced obese rodent models.
    Kawata Y; Okuda S; Hotta N; Igawa H; Takahashi M; Ikoma M; Kasai S; Ando A; Satomi Y; Nishida M; Nakayama M; Yamamoto S; Nagisa Y; Takekawa S
    Eur J Pharmacol; 2017 Feb; 796():45-53. PubMed ID: 27986627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A
    Wang W; Chen J; Mao J; Li H; Wang M; Zhang H; Li H; Chen W
    J Agric Food Chem; 2018 Jun; 66(23):5853-5859. PubMed ID: 29771124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.